<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756791</url>
  </required_header>
  <id_info>
    <org_study_id>SAPLIA</org_study_id>
    <nct_id>NCT04756791</nct_id>
  </id_info>
  <brief_title>Prospective Comparison of Single-Injection Serratus Anterior Plane Block With Ropivacaine Versus Local Infiltration of Anaesthetic After Breast Surgery</brief_title>
  <acronym>SAPLIA</acronym>
  <official_title>Prospective Comparison of Single-Injection Serratus Anterior Plane Block With Ropivacaine Versus Local Infiltration of Anaesthetic After Breast Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether a serratus anterior plane block (SAPB) is more effective than a local&#xD;
      infiltration anesthesia (LIA) with an equal dose and same anesthetic performed by the&#xD;
      surgeon, as an adjuvant to treat postoperative pain after unilateral mastectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate whether a serratus anterior plane block (SAPB) is more effective than a local&#xD;
      infiltration anesthesia (LIA) with an equal dose and same anesthetic performed by the&#xD;
      surgeon, as an adjuvant to treat postoperative pain after unilateral mastectomy.&#xD;
&#xD;
      Primary endpoint: the use of opioid's in the postoperative period. Secondary endpoint:&#xD;
      Numerical Pain Rating Scale (NPRS) score recorded at the 2nd, 8th, 16th, 24th hour after&#xD;
      surgery. 0 means no pain and 10 is the worst pain imaginable. In addition at the same time,&#xD;
      we will look to the degree of arm mobilization where there will be 3 possible groups: 1.&#xD;
      restricted, 2. fair mobilization and 3. free mobilization.&#xD;
&#xD;
      There are 2 treatment arms: 1st arm is the standard therapy, namely the local infiltration&#xD;
      anesthesia. 2nd arm is the experimental arm, namely the SAPB. Patients are randomised into&#xD;
      each arm after screening.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The use of opioids in the postoperative period</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients receive a patient controlled intravenous anesthesia pump with morphine. We will be able to analyze the total amount of opioid requested by the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Pain Rating Scale</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients will be asked at 4 different time points the amount of pain they are feeling on a scale of 0 to 10. 0 meaning no pain and 10 meaning the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of arm mobilization</measure>
    <time_frame>24 hours</time_frame>
    <description>How much can the arm be mobilized of the patients? 3 groups: 1: restricted, 2: fair mobilization and 3. free mobilization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Mastectomy; Lymphedema</condition>
  <arm_group>
    <arm_group_label>Local infiltration anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive local infiltration anesthesia with ropivacaine placed by surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serratus anterior plane block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a SAPB with ropivacaine placed by anesthesiologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SAPB</intervention_name>
    <description>local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.</description>
    <arm_group_label>Serratus anterior plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local Injection Anesthesia</intervention_name>
    <description>Anesthesia is injected directly into the tissue that is will be numbing.</description>
    <arm_group_label>Local infiltration anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years.&#xD;
&#xD;
          -  Provision of signed informed consent prior to any study-specific procedure.&#xD;
&#xD;
          -  Patients who come to preoperative anesthesia consultation for their scheduled&#xD;
             unilat-eral mastectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt;80 years&#xD;
&#xD;
          -  History of chronic pain or drug treatment abuse&#xD;
&#xD;
          -  Depression, psychiatric morbidity or mal-adaptive coping behavior&#xD;
&#xD;
          -  Neuropathy&#xD;
&#xD;
          -  Severe anxiety or other mental ailment, taking drugs affecting their capacity to&#xD;
             assess pain&#xD;
&#xD;
          -  Chronic or acute skin infection of the lateral thorax&#xD;
&#xD;
          -  Hypersensitivity to ropivacaine&#xD;
&#xD;
          -  Severe hepatic or renal disease&#xD;
&#xD;
          -  Refuse to participate to the study&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evelien Vandeurzen</last_name>
    <phone>192 92 37</phone>
    <email>evelien.vandeurzen@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelien Vandeurzen, Master</last_name>
      <phone>024749237</phone>
      <email>evelien.vandeurzen@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Kinnaer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brecht Bockstael, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

